IHC of GATA-3 on an FFPE Breast Carcinoma Tissue
| Intended Use | For In Vitro Diagnostic Use | |||||||||||||||||||||||||||||||||||
| Summary and Explanation | Trans-acting T-cell-specific transcription factor, GATA-3 is, a protein that in humans is encoded by the GATA3 gene. GATA-3 b regulates luminal epithelial cell differentiation in the mammary gland, is an important regulator of T cell development and plays an important role in endothelial cell biology.GATA-3 is one of the three genes mutated in 10% of breast cancers. Nuclear expression of GATA-3 in breast cancer is considered a marker of luminal cancer in ER+ cancer and luminal androgen responsive cancer in ER-/AR+ tumors. It is highly coexpressed with FOXA1 and serves as negative predictor of basal subtype and HER-2 and is also considered a strong predictor of taxane and platin salts insensitivity.GATA3 expression is found in urothelial carcinoma, especially in invasive and high grade tumors. Therefore, anti-GATA3 can be used in a panel of antibodies for diagnosis of unknown primary carcinoma, when carcinomas of the breast or bladder are a possibility. Studies have also shown the utility of GATA-3 in differntiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine, cervix, anus and lung. | |||||||||||||||||||||||||||||||||||
| Antibody Type | Mouse Monoclonal | Clone | L50-823 | |||||||||||||||||||||||||||||||||
| Isotype | IgG1/K | Reactivity | Paraffin, Frozen | |||||||||||||||||||||||||||||||||
| Localization | Nuclear | Control | Breast Carcinoma | |||||||||||||||||||||||||||||||||
| Presentation | GATA3 clone L50-823 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative. | |||||||||||||||||||||||||||||||||||
| Availability |
| |||||||||||||||||||||||||||||||||||
| Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product. | ||||||||||||||||||||||||||||||||||||
